CME online

The Primary Prevention of CHF and CKD in Diabetes
Agenda

Introduction

Epidemiology and Pathophysiology of HF
Mikhail N. Kosiborod, MD

Preventing HF & HF Adverse Outcomes: A Look at the Evidence
Javed Butler, MD

The Present and Future Management of HFrEF and HFpEF
Biykem Bozkurt, MD, PhD

Panel Discussion: Practical Management of HF – Case-Based
Panel: Biykem Bozkurt, MD, PhD • Yehuda Handelsman, MD • Mikhail N. Kosiborod, MD • Christian W. Mende, MD • Muthiah Vaduganathan, MD
Moderator: Javed Butler, MD

Faculty

Javed Butler, MD, MPH, MBA Chair

Patrick H. Lehan Chair in Cardiovascular Research
Professor and Chairman, Department of Medicine
University of Mississippi Medical Center
Jackson, Mississippi

Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE Chair

4th Heart in Diabetes
Medical Director & Principal Investigator,
The Metabolic Institute of America
Tarzana, California

Biykem Bozkurt, MD, PhD, FHFSA, FACC, FAHA, FESC, FACP

President, Heart Failure Society of America
The Mary and Gordon Cain Chair
W.A. “Tex” and Deborah Moncrief, Jr., Chair
Professor of Medicine
Medical Care Line Executive
DeBakey VA Medical Center
Director, Winters Center for Heart Failure Research
Associate Director, Cardiovascular Research Institute
Vice-Chair of Medicine, Baylor College of Medicine
Houston, Texas

Mikhail N. Kosiborod MD, FACC, FAHA

Professor of Medicine
Saint Luke's Mid America Heart Institute
University of Missouri-Kansas City School of Medicine
Kansas City, Missouri

Christian W. Mende, MD, FACP, FACN, FASN, FASH, FAHA

Clinical Professor of Medicine
University of California San Diego
La Jolla, California

Muthiah Vaduganathan, MD, MPH

Cardiologist,
Brigham and Women’s Hospital
Instructor of Medicine,
Harvard Medical School
Boston, Massachusetts

Program Description

Heart failure (HF) shares many pathophysiologic pathways with obesity, type 2 diabetes (T2D) and chronic kidney disease (CKD), including hypertension, dyslipidemia, inflammation, oxidative stress, and increased renin-angiotensin-aldosterone system activity. HF currently affects approximately 6.5 million individuals in the United States, but its prevalence is increasing. It is believed that nearly 9% of the population worldwide above age 60 have HF, while in people with diabetes it may reach up to 24%. Heart failure with preserved ejection fraction (HFpEF) is becoming almost as prevalent, soon to be more, as heart failure with reduced ejection fraction (HFrEF). Patients with obesity, metabolic syndrome and diabetes, especially those who also have CKD, are particularly susceptible to HF. In this CME satellite symposium we will exam the epidemiology, current CVOT relevant to HF and optimal approaches to the prevention and management of HF.

Learning Objectives

Target Audience

This educational initiative is designed for cardiologists, endocrinologists, diabetologists, internists, family physicians, nurse practitioners, physician assistants, and other healthcare professionals interested in the pathophysiology, prevention, and management of heart failure in relation to associated conditions such as obesity, diabetes, cardiovascular and kidney disease.

CME Statement

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PESI Inc., and Metabolic Endocrine Education Foundation (MEEF). PESI, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

PESI, Inc. designated this live educational activity for a maximum of 2 AMA PRA Category 1 Credit(s). Physicians should only claim credit commensurate with the extent of their participation in the activity.